Published on: July 18, 2010

Titan Pharmaceuticals has received patent from the US Patent and Trademark Office (USPTO) covering Probuphine for the treatment of opiate addiction.

Titan Pharmaceuticals is the assignee of this patent which claims a method for treating opiate addiction with a subcutaneously implanted device comprising buprenorphine and ethylene vinyl acetate, a biocompatible copolymer that releases buprenorphine continuously.

Probuphine is designed to deliver six months of continuous, therapeutic levels of buprenorphine following a single treatment.

The arrival of every new therapeutic modality should make us happy.

But we in developing countries are afraid!

Is this another expensive agent that will replace less expensive options and make life more difficult for our people?

Comments are closed.